Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: Evidence of a pressure-independent effect

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 3, 2007, Pages 205-209

  Castoldi, G ^a,b   Di Gioia, C R T ^c   Travaglini, C ^c   Busca, G ^b   Redaelli, S ^a   Bombardi, C ^a   Stella, A ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Center of Clinical Physiology and Hypertension   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiotensin II; Losartan; Renovascular hypertension; Tissue specific inhibitor of metalloproteinase 2

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; LOSARTAN; MESSENGER RNA; PROTEIN; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; NORTHERN BLOTTING; OSMOTIC MINIPUMP; PLASMA RENIN ACTIVITY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; BLOTTING, NORTHERN; CELLS, CULTURED; HYPERTENSION, RENOVASCULAR; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RENIN; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33846429977     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04573.x     Document Type: Article

References (24)

1. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2001; 38: 715-28.
2. Van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-8.
3. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 1995; 77: 863-8.
4. Lehoux S, Lemariè CA, Esposito B, Lijnen HR, Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 2004; 109: 1041-7.
5. Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 2001; 276: 3203-14.
6. Lin H, Chen X, Wang J, Yu Z. Inhibition of apoptosis in rat mesangial cells by tissue inhibitor of metalloproteinase-1. Kidney Int. 2002; 62: 60-9.
7. Seo DW, Li H, Guedez L et al. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 2003; 114: 171-80.
8. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000; 1477: 267-83.
9. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. Biol. Chem. 1990; 265: 13 933-8.
10. Browatzki M, Larsen D, Pfeiffer CAH et al. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-κB and activator protein 1 in a redox-sensitive manner. J. Vasc. Res. 2005; 42: 415-23.
11. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-52.
12. Kranzhofer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 1623-9.
13. Parmentier JH, Pavicevic Z, Malik KU. Angiotensin II stimulates phospholipase D through PKCζ activation in VSMC. Implications in adhesion, spreading and hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H46-54.
14. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003; 108: 1499-05.
15. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 1995; 95: 1353-62.
16. Castoldi G, di Gioia CRT, Pieruzzi F et al. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. Am. J. Physiol. Heart Circ. Physiol. 2003; 284: H635-43.
17. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: Potential mediators of vascular disease. Circ. Res. 2003; 92: 111-18.
18. Stetler-Stevenson WG, Seo DW. TIMP-2: An endogenous inhibitor of angiogenesis. Trends Mol. Med. 2005; 11: 97-103.
19. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J. Clin. Invest. 1999; 103: 1237-41.
20. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell Physiol. 1993; 157: 351-8.
21. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α. Am. J. Physiol. Cell Physiol. 2004; 286: C779-84.
22. Chen H, Li D, Mehta JL. Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-κB by losartan in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 2002; 39: 332-9.
23. Brassard P, Amiri F, Thibault G, Schriffin EL. Role of angiotensin type 1 and angiotensin type 2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Hypertension 2006; 47: 122-7.
24. Brassard P, Amiri F, Schriffin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005; 46: 598-606.